Study guide
8.4 USP <800> Hazardous Drug Identification and Handling Precautions
PTCB Technician Product Verification TPV
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Tech-Check-Tech Verification Fundamentals
1.1 About the PTCB TPV Certificate Exam 1.2 Tech-Check-Tech (TCT) Scope, Regulations, and Quality Assurance 1.3 Systematic Verification Protocol & Visual Inspection Steps
2 Chapter 2: Drug Name Verification & Brand/Generic Identification
2.1 Brand vs Generic Mapping, USAN Stems, and Orange Book Therapeutic Equivalence 2.2 Salt Forms and Active Ingredient Verification 2.3 Manufacturer-Specific Identification, Visual Cues, and Color Codes
3 Chapter 3: Auxiliary Labels, REMS & Controlled Substances
3.1 Auxiliary Warning Labels and Mandatory Patient Counseling Triggers 3.2 REMS Programs and Restricted Distribution Medications 3.3 Controlled Substance Scheduling, Refill Restrictions, and C-II Exact Counts
4 Chapter 4: Dosage Forms, Release Mechanisms & Administration Routes
4.1 Modified-Release Formulations (ER, XL, SR, DR, CR) and "Do Not Crush" Rules 4.2 Route of Administration Verification: Ophthalmic vs Otic, Oral vs Topical vs Transdermal 4.3 Specialized Delivery Systems: Inhalers (MDI/DPI), ODTs, Solutions vs Suspensions
5 Chapter 5: Strength Verification & Pharmaceutical Calculations
5.1 Unit Conversions (mcg, mg, g) and Preventing Leading/Trailing Zero Errors 5.2 Percentage Strengths, Ratio Strengths, and Liquid Concentrations (mg/mL) 5.3 Electrolyte Equivalents (mEq vs mg) and Combination Product Strength Verification
6 Chapter 6: High-Alert Medications & Safety Protocols
6.1 ISMP High-Alert Medications and Independent Double-Check Protocols 6.2 Insulin Formulations, Concentrations (U-100, U-500, U-200, U-300), and Pen/Vial Math 6.3 Concentrated Electrolytes, Opioids, Neuromuscular Blockers, and Oral Methotrexate
7 Chapter 7: Look-Alike / Sound-Alike (LASA) Medications
7.1 FDA and ISMP Tall-Man Lettering Principles 7.2 High-Risk Community/Ambulatory LASA Pairs 7.3 High-Risk Institutional/Hospital LASA Pairs & Packaging Traps
8 Chapter 8: Packaging, Expiration, Storage & Special Handling
8.1 Expiration Date Interpretation and Multi-Dose Vial Beyond-Use Dating (BUD) 8.2 Packaging Integrity, Moisture/Light Sensitivity, and FDA Recall Classes 8.3 Temperature Storage Ranges and Vaccine Cold Chain Integrity 8.4 USP <800> Hazardous Drug Identification and Handling Precautions
9 Chapter 9: NDC Conversion, Repackaging & Final Dispensing Checks
9.1 NDC 10-Digit to 11-Digit Conversion (5-4-2 Standardization) 9.2 Unit-Dose Repackaging Standards and USP <795> BUD Guidelines 9.3 Days Supply Calculations, Package Size Verification, and Final Label Matching
8.4 USP <800> Hazardous Drug Identification and Handling Precautions
Key Takeaways Explain This Topic AI
USP <800> sets comprehensive standards for handling Hazardous Drugs (HDs) across receipt, storage, compounding, dispensing, and disposal to protect healthcare workers, patients, and the environment.
The NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 replaced the 2016 list's three groups with two tables: Table 1 (drugs with manufacturer's special handling information and/or NTP/IARC carcinogen classification) and Table 2 (drugs meeting NIOSH criteria without MSHI, including a flag for those that are only a developmental or reproductive hazard).
HD oral solid dosage forms (tablets/capsules) MUST be counted using dedicated, clearly labeled HD counting trays and spatulas, and must NEVER be counted using automated counting machines (e.g., Kirby Lester) due to hazardous dust contamination.
Personal Protective Equipment (PPE) for HD handling requires chemotherapy gloves tested to ASTM D6978 standards, lint-free coated gowns, and N95/respirators or PAPRs for aerosol/vapor risks.
Chemotherapy waste is segregated into Yellow Trace Waste (<3% residual drug, PPE, tubing, empty vials) for high-temperature incineration and Black Bulk RCRA Waste (>3% residual volume, expired full stock, P/U-listed chemicals).
Last updated: August 2026
USP <800> Hazardous Drug Identification and Handling Precautions
Core Verification Rule: In technical product verification, a pharmacy technician must identify all hazardous drugs (HDs) listed under NIOSH Groups 1, 2, and 3 and enforce strict USP <800> containment barriers. The verifying technician must confirm that HDs are counted using dedicated, labeled equipment—never automated counting machines—and that proper ASTM D6978 chemotherapy PPE, spill containment, and yellow/black waste segregation standards are maintained.
Healthcare workers handling hazardous drugs face occupational risks including carcinogenicity, teratogenicity, reproductive toxicity, organ toxicity, and genotoxicity. USP General Chapter <800> Hazardous Drugs—Handling in Healthcare Settings establishes mandatory containment standards throughout the medication lifecycle.
1. NIOSH Hazardous Drug Classifications (2024 List — Two Tables, Not Three Groups)
The National Institute for Occupational Safety and Health (NIOSH) maintains the official list that USP <800> and most facility policies point to.
Warning
The structure changed in December 2024. The current publication is the NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 (DHHS (NIOSH) Publication No. 2025-103). It replaced the 2016 list's three groups with two tables . There is no Table 3 anymore , and "antineoplastic" is no longer used as a table descriptor. Older textbooks, courses, and practice banks still teach "Group 1 / Group 2 / Group 3" — if you see that framing, you are looking at the 2016 list. ┌────────────────────────────────────────────────────────────────────────┐
- │ NIOSH 2024 LIST -- TABLE STRUCTURE │
- ├────────────────────────────────────────────────────────────────────────┤
- │ TABLE 1 │
- │ Drugs that have manufacturer's special handling information (MSHI) │
- │ in the package insert, AND/OR meet the NIOSH hazardous drug │
- │ definition and are: │
- │ • NTP-classified "known to be a human carcinogen", OR │
- │ • IARC Group 1 "carcinogenic to humans" or Group 2A "probably │
- │ carcinogenic to humans". │
- │ NOTE: Not every Table 1 drug is an antineoplastic. │
- │ Examples: methotrexate, cyclophosphamide, fluorouracil, cisplatin, │
- │ doxorubicin, vincristine, tamoxifen, capecitabine, mercaptopurine, │
- │ azathioprine, cyclosporine, ganciclovir. │
- │ │
- │ TABLE 2 │
- │ Drugs that meet one or more NIOSH hazardous drug criteria but │
- │ (1) have no MSHI, (2) are not NTP "known human carcinogens", and │
- │ (3) are not IARC Group 1 or 2A. A separate column flags the drugs │
- │ that are ONLY a developmental and/or reproductive hazard -- the │
- │ population that used to sit in the retired Table 3. │
- │ Examples: spironolactone, carbamazepine, phenytoin, estradiol, │
- │ tacrolimus, finasteride, dutasteride, warfarin, misoprostol, │
- │ clonazepam, paroxetine, letrozole, fluconazole. │
- └────────────────────────────────────────────────────────────────────────┘
- What Moved in the 2024 Update
The 2024 update added 25 drugs (12 of them with MSHI) and removed 7 . Several drugs technicians handle routinely also changed tables:
Drug 2016 List 2024 List Practical Effect
Azathioprine (Imuran) Group 2 Table 1 Now grouped with the highest-containment agents (IARC Group 1 carcinogen).
Cyclosporine (Neoral / Gengraf) Group 2 Table 1 Same — IARC Group 1 carcinogen.
Ganciclovir (Cytovene) Group 2 Table 1 Has MSHI in the package insert.
Finasteride (Proscar / Propecia) Group 3 Table 2 , flagged developmental/reproductive Handling precautions unchanged in practice; the table label changed.
Warfarin (Coumadin / Jantoven) Group 3 Table 2 , flagged developmental/reproductive Still a hazardous drug and still P-listed RCRA waste.
Comprehensive NIOSH Hazardous Drug Reference Table
NIOSH 2024 Table Basis for Listing Representative Drug Examples Clinical / Verification Checkpoint
Table 1 MSHI in the insert, and/or NTP "known human carcinogen" or IARC Group 1 / 2A • Methotrexate (Trexall); • Cyclophosphamide (Cytoxan); • Fluorouracil (5-FU); • Tamoxifen (Soltamox); • Capecitabine (Xeloda); • Mercaptopurine (Purinethol); • Azathioprine (Imuran); • Cyclosporine (Neoral / Gengraf) High risk of secondary malignancies and bone marrow suppression. Oral methotrexate for rheumatoid arthritis is dosed WEEKLY (daily dosing causes fatal toxicity).
Table 2 Meets NIOSH criteria; no MSHI; not NTP/IARC classified as above • Spironolactone (Aldactone); • Carbamazepine (Tegretol); • Estradiol (Estrace / Climara); • Phenytoin (Dilantin); • Tacrolimus (Prograf) Diuretics, anticonvulsants, hormones, and immunosuppressants meeting organ toxicity, genotoxicity, or carcinogenicity criteria.
Table 2 , flagged "only developmental and/or reproductive hazard" Meets NIOSH criteria solely as a developmental/reproductive hazard • Finasteride (Proscar / Propecia); • Dutasteride (Avodart); • Warfarin (Coumadin); • Misoprostol (Cytotec); • Clonazepam (Klonopin); • Paroxetine (Paxil) 5-alpha reductase inhibitors (finasteride, dutasteride) can cause genital abnormalities in a developing male fetus, so personnel who are pregnant or trying to conceive must not handle crushed or broken tablets.
A caution about local policy: USP <800> and many facility policies were written against the 2016 three-group framework and have not all been rewritten. Follow your facility's current Assessment of Risk and hazardous drug list; use the NIOSH 2024 tables to understand why a drug is on it, not to overrule a stricter local standard.
2. Handling, Counting, and Dispensing Precautions
To prevent occupational cross-contamination and unintended exposure, pharmacies must adhere to strict physical handling protocols for hazardous solid dosage forms. ┌────────────────────────────────────────────────────────────────────────┐
- │ HD DISPENSING & COUNTING RULES │
- ├────────────────────────────────────────────────────────────────────────┤
- │ 1. DEDICATED COUNTING TRAYS & SPATULAS: │
- │ • Must use a dedicated tray and spatula labeled 'HAZARDOUS ONLY'. │
- │ • Trays are often color-coded (e.g., bright red or yellow). │
- │ │
- │ 2. AUTOMATED COUNTING MACHINES STRICTLY PROHIBITED: │
- │ • NEVER pour hazardous tablets/capsules into automated counting │
- │ machines (e.g., Kirby Lester, Baker Cells, robot dispensers). │
- │ • Rationale: Tablet friction generates microscopic hazardous dust │
- │ that contaminates subsequent non-hazardous drugs and exposes staff│
- │ │
- │ 3. DECONTAMINATION & CLEANING PROTOCOL: │
- │ • 70% Isopropyl Alcohol (IPA) ALONE DOES NOT DECONTAMINATE! │
- │ • Decontamination requires an oxidizing agent (bleach/peroxide), │
- │ followed by neutralizing cleaner, then 70% IPA for disinfection. │
- └────────────────────────────────────────────────────────────────────────┘
Caution
The Kirby Lester / Automation Dust Hazard: Counting hazardous tablets (such as methotrexate, spironolactone, or finasteride) in automated counting machines creates invisible aerosolized powder. When a subsequent non-hazardous medication (such as amlodipine) is counted in that same machine, the hazardous chemical residue is transferred directly into the patient's prescription, while technician inhalation of dust creates cumulative systemic toxicity.
3. Personal Protective Equipment (PPE) Standards
USP <800> specifies strict PPE requirements based on the activity being performed (e.g., receiving, counting intact tablets, compounding, or managing spills). ┌────────────────────────────────────────────────────────────────────────┐
- │ USP <800> PPE REQUIREMENTS │
- ├────────────────────────────────────────────────────────────────────────┤
- │ • CHEMOTHERAPY GLOVES: │
- │ - Must be powder-free and tested to ASTM D6978 standards. │
- │ - For compounding/spills: Double gloves (outer over cuff, inner │
- │ under cuff); change gloves every 30 MINUTES. │
- │ - For counting intact HDs: At least 1 pair ASTM D6978 gloves. │
- │ │
- │ • CHEMOTHERAPY GOWNS: │
- │ - Disposable, lint-free, polyethylene-coated (impermeable). │
- │ - Back-closing with long sleeves and elastic/knit cuffs. │
- │ - Change every 2 to 3 HOURS (or immediately if contaminated). │
- │ │
- │ • RESPIRATORY & EYE PROTECTION: │
- │ - N95 respirator protects against airborne HD dust particles. │
- │ - PAPR (Powered Air-Purifying Respirator) or gas cartridge mask │
- │ required for HD vapors, gases, or major spills. │
- │ - Goggles / full face shield required when splash risk exists. │
- └────────────────────────────────────────────────────────────────────────┘
- 4. Waste Disposal Segregation: Yellow Trace vs. Black Bulk RCRA
Disposal of hazardous drug residue is governed by both USP <800> and Environmental Protection Agency (EPA) Resource Conservation and Recovery Act (RCRA) regulations.
Waste Container Container Type & Color Waste Content Classification Representative Disposal Items
YELLOW TRACE WASTE Yellow Rigid Container (or Yellow Chemo Bag) Trace Chemotherapy Waste (< 3% residual volume by weight) • Empty IV bags and tubing; • Used chemotherapy gloves and gowns; • Empty vials (<3% drug remaining); • Needles, syringes, chemo wipes; • Contaminated counting tray paper
BLACK BULK RCRA WASTE Black Rigid Hazardous Container Bulk Hazardous / RCRA Waste (> 3% residual volume or unempty) • Partially used / expired HD vials (>3% volume); • Unused chemotherapy doses; • P-listed acute hazardous chemical waste (Warfarin, Nicotine, Physostigmine); • Hazardous chemical compounding spill debris